Search Results - "Horwood, K"

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors by Makarious, D., Horwood, K., Coward, J.I.G.

“…The advent of immunotherapy has heralded a number of significant advances in the treatment of particular malignancies associated with poor prognosis (melanoma,…”
Get full text

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses by Mitchell, P., Thatcher, N., Socinski, M.A., Wasilewska-Tesluk, E., Horwood, K., Szczesna, A., Martín, C., Ragulin, Y., Zukin, M., Helwig, C., Falk, M., Butts, C., Shepherd, F.A.

“…Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit…”
Get full text

Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival by Obermair, A, Cheuk, R, Horwood, K, Neudorfer, M, Janda, M, Giannis, G, Nicklin, J L, Perrin, L C, Crandon, A J

“…To determine the impact of anemia before and during chemoradiation in patients with cervical cancer, we collected data on hemoglobin (Hb) levels before and…”
Get more information

Prognostic gene expression signature for high-grade serous ovarian cancer by Intermaggio, M.P., Leong, H.S., Chen, S., Elatre, W., Gilks, B., Volchek, M., Wang, C., Mackenzie, R., George, J., Bowtell, D., Chenevix-Trench, G., Green, A., Gertig, D., Fereday, S., Moore, S., Hung, J., Harrap, K., Malt, M., Robertson, R., Maidens, J., Jayde, V., Mamers, P., Schmidt, T., Ball, C., Bilic, Sanela, Stuart-Harris, R., Clingan, P., Glasgow, A., Shannon, J., Young, B., Robertson, G., Carter, J., Dalrymple, C., Russell, P., Links, M., Jaworski, R., Crandon, A., Horwood, K., Obermair, A., Wyld, D., Davy, M., Dodd, T., Healy, T., Pittman, K., Henderson, D., Pierdes, J., Brown, B., Hyde, S., Healy, D., McNealage, J., Simpson, I., Fox, S., Lade, S., Loughrey, M., Neesham, D., Bell, R., Ng, L.F., Whiteman, D., Fereday, S., Steed, H., Koziak, J.M., Goranova, T., Silva De Silva, D., Ramón y Cajal, T., García-Donas, J., Rodriguez, G.C., Harris, H.R., Greene, C.S., Zelaya, R.A., Sinn, P., Menkiszak, J., Pearce, C.L., Rhenius, V., Piskorz, A.M., Sharma, R., Johnatty, S.E., Larson, M.C., Luk, H., Hernandez, B.Y., Thompson, P.J., Sherman, M.E., Bodelon, C., Lewsley, L.A., Banerjee, S.N., Stronach, E.A., Haluska, P., Ray-Coquard, I., Winterhoff, B., Slamon, D., Levine, D.A., Menon, U., Goodman, M.T., Schildkraut, J.M., Brown, R., Berchuck, A., Chenevix-Trench, G., deFazio, A., Beeghly-Fadiel, A., Fasching, P.A., Orsulic, S.

“…Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no…”
Get full text

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses by Cheasley, Dane, da Cunha Torres, Michelle, Salazar, Carolina, Xing, Zhongyue, Mes-Masson, Anne-Marie, Provencher, Diane M., Rahimi, Kurosh, Fasching, Peter A., Goodman, Marc T., Deen, Suha, Sieh, Weiva, Mateoiu, Constantina, Cook, Linda S., Le, Nhu D., Anglesio, Michael S., Chenevix-Trench, G., Traficante, N., Harrap, K., Sadkowsky, T., Mellon, A., Jones, M., Green, L., Ranieri, B., White, J., Bowes, L., Galletta, L., Giles, D., Hendley, J., Alsop, K., Young, C., Viduka, S., Glavinas, Lydia, Rutovitz, J., Glasgow, A., Bonaventura, T., Begbie, S., Baron-Hay, S., Nevell, D., Valmadre, S., Marsden, D., Beale, P., Beith, J., Carter, J., Dalrymple, C., Brand, A., Byth, K., Jaworski, R., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Perrin, L., Wyld, D., Davy, M., Oehler, M.K., Hall, C., Henderson, D., Miller, J., Blomfield, P., Rome, R., Grant, P., Laurie, R., Robbie, M., Manolitsas, T., McNealage, J., Susil, B., Sumithran, E., Phillips, K., Rischin, D., Fox, S., Loughrey, M., Billson, V., Neesham, D., Quinn, M., Blum, R., Leung, Y., Buck, M., Purdie, D., Ramus, Susan J., Scott, Clare L., Köbel, Martin, Gorringe, Kylie L., Allan, Prue E., Böhm, Maret, Christie, Michael, DeFazio, Anna, Fairweather, Nicole, Hadley, Alison M., Hendley, Joy, Ho, Gwo-Yaw, Huntsman, David G., Jobling, Tom W., Kennedy, Catherine J., Le Page, Cecile, Pyman, Jan, Rahimi, Kurosh, Samimi, Goli, Sharma, Ragwha, Antill, Yoland C., Gorringe, Kylie L.

“…TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry…”
Get full text

Primary vaginal non‐Hodgkin's lymphoma after radiotherapy for Hodgkin's disease by HORWOOD, K. R., SAMARATUNGA, H.

Get full text

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer by Winham, Stacey J., Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G., Sinn, Peter, Rothstein, Joseph H., Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Nelson, Gregg, Menkiszak, Janusz, Longacre, Teri A., Li, Zheng, Lester, Jenny, Kennedy, Catherine J., Kalli, Kimberly R., Johnatty, Sharon E., Jensen, Allan, Hung, Jillian, Herpel, Esther, Hernandez, Brenda Y., Hartkopf, Andreas D., de Andrade, Jurandyr M., Chudecka-Głaz, Anita, Brucker, Sara Y., Bowtell, D., Webb, P., Gertig, D., Fereday, S., Moore, S., Harrap, K., Pandeya, N., Malt, M., Mellon, A., Robertson, R., Vanden Bergh, T., Brown, S., Green, L., Ferguson, K., Martyn, A., Ball, C., Bilic, Sanela, Stuart-Harris, R., Glasgow, A., Proietto, A., Braye, S., Shannon, J., Ferrier, A., Nevell, D., Valmadre, S., Young, B., Crouch, R., Robertson, G., Carter, J., Dalrymple, C., Houghton, R., Grygiel, J., Jaworski, R., Harnett, P., Wain, G., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Obermair, A., Davy, M., Dodd, T., Henderson, D., Pierdes, J., Brown, B., Allen, D., Grant, P., Robbie, M., Healy, D., Jobling, T., McNealage, J., Fox, S., Lade, S., Loughrey, M., O'Callaghan, N., Murray, W., Neesham, D., Bell, R., Ganju, V., Buck, M., Whiteman, D., Whittemore, Alice S., Steed, Helen, Kjaer, Susanne K., Kelemen, Linda E., Karlan, Beth Y., Huntsman, David G., Høgdall, Estrid, Gronwald, Jacek, Fasching, Peter A., Chang-Claude, Jenny, Campbell, Ian G., Pharoah, Paul D.P., Ramus, Susan J., Goode, Ellen L.

“…To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial…”
Get full text

Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer by Merritt, Melissa A., Green, Adèle C., Nagle, Christina M., Webb, Penelope M.

“…Chronic inflammation has been proposed as the possible causal mechanism that explains the observed association between certain risk factors, such as the use of…”
Get full text

Urban Green Space Special Edition Guest Editorial by Horwood, K., von Benzon, N.

Get full text

Consortium analysis of 7 candidate SNPs for ovarian cancer by Ramus, Susan J., Vierkant, Robert A., Johnatty, Sharon E., Pike, Malcolm C., Van Den Berg, David J., Wu, Anna H., Pearce, Celeste Leigh, Menon, Usha, Gentry‐Maharaj, Aleksandra, Gayther, Simon A., DiCioccio, Richard A., McGuire, Valerie, Whittemore, Alice S., Song, Honglin, Easton, Douglas F., Pharoah, Paul D.P., Garcia‐Closas, Montserrat, Chanock, Stephen, Lissowska, Jolanta, Brinton, Louise, Terry, Kathryn L., Cramer, Daniel W., Tworoger, Shelley S., Hankinson, Susan E., Berchuck, Andrew, Moorman, Patricia G., Schildkraut, Joellen M., Cunningham, Julie M., Liebow, Mark, Kjaer, Susanne Krüger, Hogdall, Estrid, Hogdall, Claus, Blaakaer, Jan, Ness, Roberta B., Moysich, Kirsten B., Edwards, Robert P., Carney, Michael E., Lurie, Galina, Goodman, Marc T., Wang‐Gohrke, Shan, Kropp, Silke, Chang‐Claude, Jenny, Webb, Penelope M., Chen, Xiaoqing, Beesley, Jonathan, Chenevix‐Trench, Georgia, Goode, Ellen L.

“…The Ovarian Cancer Association Consortium selected 7 candidate single nucleotide polymorphisms (SNPs), for which there is evidence from previous studies of an…”
Get full text

RE: A phase I trial of radiation dose escalation using accelerated concomitant boost radiotherapy concurrently with weekly carboplatin/paclitaxel in patients with good performance status and Stage IIB-IIIA/B non-small cell lung cancer by LEHMAN, M, HORWOOD, K, BURMEISTER, B, ZARATE, D, DAUTH, M

Get full text

Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set by BEESLEY, Jonathan, JORDAN, Susan J, GAYTHER, Simon A, PHAROAH, Paul D. P, WEBB, Penelope M, CHENEVIX-TRENCH, Georgia, SPURDLE, Amanda B, HONGLIN SONG, RAMUS, Susan J, KRUGER KJAER, Suzanne, HOGDALL, Estrid, DICIOCCIO, Richard A, MCGUIRE, Valerie, WHITTEMORE, Alice S

“…Although some high-risk ovarian cancer genes have been identified, it is likely that common low penetrance alleles exist that confer some increase in ovarian…”
Get full text

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium by Pearce, C L, Near, A M, Van Den Berg, D J, Ramus, S J, Gentry-Maharaj, A, Menon, U, Gayther, S A, Anderson, A R, Edlund, C K, Wu, A H, Chen, X, Beesley, J, Webb, P M, Holt, S K, Chen, C, Doherty, J A, Rossing, M A, Whittemore, A S, McGuire, V, DiCioccio, R A, Goodman, M T, Lurie, G, Carney, M E, Wilkens, L R, Ness, R B, Moysich, K B, Edwards, R, Jennison, E, Kjaer, S K, Hogdall, E, Hogdall, C K, Goode, E L, Sellers, T A, Vierkant, R A, Cunningham, J C, Schildkraut, J M, Berchuck, A, Moorman, P G, Iversen, E S, Cramer, D W, Terry, K L, Vitonis, A F, Titus-Ernstoff, L, Song, H, Pharoah, P D P, Spurdle, A B, Anton-Culver, H, Ziogas, A, Brewster, W, Galitovskiy, V, Chenevix-Trench, G

“…The search for genetic variants associated with ovarian cancer risk has focused on pathways including sex steroid hormones, DNA repair, and cell cycle control…”
Get full text

Body size and risk of epithelial ovarian and related cancers: A population‐based case‐control study by Olsen, Catherine M., Nagle, Christina M., Whiteman, David C., Purdie, David M., Green, Adèle C., Webb, Penelope M.

“…Different subtypes of ovarian cancer appear to have different causes; however, the association between body mass index (BMI) and the different subtypes is…”
Get full text

The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC) by Groen, H., Arrieta, O. G., Riska, H., Horwood, K., Mali, P., Reck, M.

“…Abstract only…”
Get full text

Filters for linear sea-wave prediction by Belmont, M.R., Horwood, J.M.K., Thurley, R.W.F., Baker, J.

“…Deterministic sea-wave prediction (DSWP) models are appearing in the literature designed for quiescent interval prediction in marine applications dominated by…”
Get full text

Skewed X Chromosome Inactivation and Breast and Ovarian Cancer Status: Evidence for X-Linked Modifiers of BRCA1 by Lose, Felicity, Duffy, David L., Kay, Graham F., Kedda, Mary A., Spurdle, Amanda B.

“…Background X chromosome inactivation, which silences gene expression from one of the two X chromosomes in females, is usually random. Skewed X inactivation has…”
Get full text

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses by Mitchell, P, Thatcher, N, Socinski, M A, Wasilewska-Tesluk, E, Horwood, K, Szczesna, A, Martín, C, Ragulin, Y, Zukin, M, Helwig, C, Falk, M, Butts, C, Shepherd, F A

“…Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit…”
Get full text

Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: Preliminary results by OBERMAIR, Andreas, CHEUK, Robyn, HORWOOD, Keith, JANDA, Monika, BACHTIARY, Barbara, SCHWANZELBERGER, Barbara, STOIBER, Alexander, NICKLIN, James L, PERRIN, Lewis C, CRANDON, Lex J

“…In patients undergoing radiation for cervical carcinoma, there is evidence that anemia is associated with an impaired outcome. For patients undergoing…”
Get full text

Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study by Gatzemeier, U., Ardizzoni, A., Horwood, K., van Meerbeeck, J., Magyar, P., Gottfried, M., Arrieta, O., Krzakowski, M., Franke, F., van Zandwijk, N.

“…Abstract only 7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly prolonged survival, delayed symptom progression, and…”
Get full text